Luis
Inventors;
Applicant
PI0504517-7
Publication
International
Date:
20 October 2006 (20.10.2006)
Filing Language: English
Priority Data: P10504517-7 20 October 2005 (20.10.2005) BR
Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UC, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
- of inventorship (Rule 4.17(iv))

Published:
- with international search report
- with amended claims

Date of publication of the amended claims: 28 June 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Title: PHARMACEUTICAL COMPOSITIONS CONTAINING ERYTHRINE MULUNGU DERIVATIVES AND PROCESSES FOR THEIR PRODUCTION

Abstract: The present invention provides the use of molecules for cholinergic serotonergic and/or gabaergic system models, revealing pharmaceutical compositions comprising 11-OH-erythravine, erythravine, erythratine, pharmaceutically acceptable isomers, salts, byproducts and/or solvates thereof, optionally containing other Erythrine byproducts, for the treatment of anxiety disorders; processes for obtaining said pharmaceutical compositions
AMENDED CLAIMS
received by the International Bureau on 17 April 2007 (17.04.07)

1 - Use, in the preparation of a medicament for the modulation of cholinergic and/or serotonergic and/or gabaergic system of vertebrates, of an active ingredient characterized for presenting general formula:

![Chemical Structure]

or their isosters, salts, derivatives and/or their pharmaceutically acceptable, solvates.

2 - Use, according to claim 1, characterized by the fact that said a medicament additionally comprises the substances erythravine and/or erythartine.

3 - Use, according to claims 1 or 2, characterized by the fsici that the active substances are present in a crude standardized vegetable extract comprising:
   - at least 0.1% of total erythrinic alkaloid, wherein a purified fraction comprising, at least, 20% of total alkaloid; and
   - at least 10% of total erythrinic alkaloid expressed in erythravine, or their isosters, salts, and/or their pharmaceutically acceptable solvates,

4 - Pharmaceutical composition for the treatment of disturbances associated to cholinergic and/or serotonergic and/or gabaergic system dysfunctions characterized by comprising a pharmaceutically acceptable vehicle and at least one active substance of general formula:
or their isosters, salts, derivatives and/or their pharmaceutically acceptable solvates.

5 - Pharmaceutical composition, according to claim 4, characterized by additionally comprising the substances erythravine and/or erythartine.

6 - Pharmaceutical composition, according to claims 4 or 5, characterized by the fact that the active substances are present in a crude standardized vegetable extract comprising:
- at least 0.1% of total erythrinic alkaloid, wherein a purified fraction comprising, at least, 20% of total alkaloid; and
- at least 10% of total erythrinic alkaloid expressed in erythravine, or their isosters, salts, and/or their pharmaceutically acceptable solvates.

7 - Pharmaceutical composition, according to claims 4, 5 or 6, characterized by the fact that the crude standardized vegetable extract is a hydroalcoholic extract of Erythrina mulungu.

8 - Process of production of a pharmaceutical composition for the modulation of cholinergic system and/or serotonergic and/or gabaergic of vertebrates characterized by comprising the steps of:
- Preparation of a pharmaceutically acceptable vehicle; and
- Incorporation, to referred vehicle, of at least one active substance of general formula:
or their isosters, salts, derivates and/or their solvates pharmaceutically acceptable.

9 - Process, according to claim 8, characterized by the fact that the incorporation of step b) additionally comprise the incorporation of the substances erythravine and/or erythrartine.

10 - Process, according to claims 8 or 9, characterized by the fact that the active substances of step b) are obtained by chemical synthesis.

11 - Process, according to claim 8 or 9, characterized by the fact that the active substances of step b) are obtained by the hydroalcoholic extraction of plants of Erythrina genus.

12 - Process, according to claim 11, characterized by the fact that the active substances of step b) are obtained by the hydroalcoholic extraction of Erythrina mulungu plants.